These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 15979830)

  • 1. Paediatric formulations--getting to the heart of the problem.
    Standing JF; Tuleu C
    Int J Pharm; 2005 Aug; 300(1-2):56-66. PubMed ID: 15979830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in availability of paediatric medicines in Australia between 1998 and 2002.
    Chui J; Tordoff J; Reith D
    Br J Clin Pharmacol; 2005 Jun; 59(6):736-42. PubMed ID: 15948941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extemporaneous drug formulations.
    Nahata MC; Allen LV
    Clin Ther; 2008 Nov; 30(11):2112-9. PubMed ID: 19108799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
    Pabari RM; McDermott C; Barlow J; Ramtoola Z
    Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation of medicines for children.
    Nunn T; Williams J
    Br J Clin Pharmacol; 2005 Jun; 59(6):674-6. PubMed ID: 15948931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.
    Glass BD; Haywood A
    J Pharm Pharm Sci; 2006; 9(3):398-426. PubMed ID: 17207422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids.
    Ghulam A; Keen K; Tuleu C; Wong IC; Long PF
    Ann Pharmacother; 2007 May; 41(5):857-60. PubMed ID: 17440007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration.
    Cole ET; Cadé D; Benameur H
    Adv Drug Deliv Rev; 2008 Mar; 60(6):747-56. PubMed ID: 18096270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
    Brion F; Nunn AJ; Rieutord A
    Acta Paediatr; 2003 Apr; 92(4):486-90. PubMed ID: 12801118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - A promising starting point for future PUMA applications.
    Freerks L; Sommerfeldt J; Löper PC; Klein S
    Eur J Pharm Biopharm; 2020 Nov; 156():11-19. PubMed ID: 32871197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paediatric Drug Development and Formulation Design-a European Perspective.
    Van Riet-Nales DA; Kozarewicz P; Aylward B; de Vries R; Egberts TC; Rademaker CM; Schobben AF
    AAPS PharmSciTech; 2017 Feb; 18(2):241-249. PubMed ID: 27270905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inappropriate oral formulations and information in paediatric trials.
    Pandit S; Shah U; Kirby DJ; Nunn T; Tuleu C
    Arch Dis Child; 2010 Sep; 95(9):754-6. PubMed ID: 20605870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing paediatric medicines: identifying the needs and recognizing the challenges.
    Ernest TB; Elder DP; Martini LG; Roberts M; Ford JL
    J Pharm Pharmacol; 2007 Aug; 59(8):1043-55. PubMed ID: 17725846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs.
    Lam MS
    Pharmacotherapy; 2011 Feb; 31(2):164-92. PubMed ID: 21275495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002.
    Balakrishnan K; Grieve J; Tordoff J; Norris P; Reith D
    J Clin Pharmacol; 2006 Sep; 46(9):1038-43. PubMed ID: 16920899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of appropriate formulations of medicines for children in the community.
    Schirm E; Tobi H; de Vries TW; Choonara I; De Jong-van den Berg LT
    Acta Paediatr; 2003 Dec; 92(12):1486-9. PubMed ID: 14971804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific aspects of gastro-intestinal transit in children for drug delivery design.
    Bowles A; Keane J; Ernest T; Clapham D; Tuleu C
    Int J Pharm; 2010 Aug; 395(1-2):37-43. PubMed ID: 20478372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.